Cypralis is developing of a novel category of small molecule drugs that inhibit cyclophilins, a large family of proteins involved in many diseases. 

The company has IP on three distinct classes of small molecules that share potent inhibition of cyclophilins span a wide range of molecular weights, solubility, isoenzyme specificity and PK properties (including crossing the blood-brain barrier). We use these compounds as tools to validate inhibition of cyclophilins as novel therapeutic approach to treat diseases and as starting points for specific medicinal chemistry programmes.

A first development project CC-4066 is scheduled to enter clinical trials in Q1 2020 to prevent delayed graft function following kidney transplantation, preservation of organs for transplantation, and acute pancreatitis.